Lisata Therapeutics, Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Gets 5T4-Targeted NK Cell Therap

With its first product on track for approval soon in Japan, Caladrius Biosciences Inc. is planning its transition over the next three years from a late-stage developer of cell therapies to one comme

Immuno-oncology continues to keep FDA’s oncology staff occupied, with last week bringing news that Bristol-Myers Squibb Co. ’s Opdivo / Yervoy combination is under review for a first-line non-small